Current Issue : April-June Volume : 2025 Issue Number : 2 Articles : 1 Articles
The abundant nutrients and health benefits of Urtica dioica are known to benefit people with diabetes. However, their mechanisms of action are not precise. To address this issue, network pharmacology has been used to identify various bioactive compounds from U. dioica that can be used to treat diabetic conditions. Gas chromatography-mass spectrometry (GC-MS) was used to investigate the compounds in U. dioica and Lipinski's rule was used to screen the compounds. A molecular docking study was conducted to assess the affinity between the compounds and genes. Genes associated with the compounds and type 2 diabetes mellitus (TY2DM) targets were extracted and overlapping genes between U. dioica-associated genes and TY2DM targets were identified using Venn diagrams. Using Cytoscape, we built, visualized and analyzed a network of compounds and genes. The GC-MS analysis of U. dioicarevealed the presence of eight compounds. Compound-related genes (81) and TY2DM-related genes (13,835) were identified and 31 genes overlapped. Based on gene set enrichment, six signaling pathways were involved in the mechanisms of action of U. dioica against TY2DM and the activation of HIF-1A and VEGF is the fundamental mechanism by which the body controls its blood sugar levels. In addition, the highest affinity was found for five main compounds and six gene variants, namely NOS2- Androsta-1,4-diene-3,17-dione, EGFR- Stigmasterol, HIF1A- Stigmasterol, PRKCA- Berberine, KDR-glafenine and PTGS2- isoarborinol. It has been suggested that U. dioica contains five compounds that may help alleviate the symptoms of TY2DM and its complications, mainly by activating the HIF-1A and VEGF pathways....
Loading....